<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880512</url>
  </required_header>
  <id_info>
    <org_study_id>SYHX1902-CSP-001</org_study_id>
    <nct_id>NCT04880512</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects</brief_title>
  <official_title>A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC Ouyi Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic&#xD;
      characteristics of single ascending doses and multiple ascending doses of SYHX1901 tablets in&#xD;
      Chinese healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled study to evaluate the safety,&#xD;
      tolerability and pharmacokinetic characteristics of single ascending doses (part 1) and&#xD;
      multiple ascending doses (part 2) of SYHX1901 tablets in Chinese healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SYHX1901 tablets</measure>
    <time_frame>SAD: up to14 days after the dosing, MAD: up to 7 days after the last dosing</time_frame>
    <description>The safety and tolerability of single or multiple doses of SYHX1901 tablets administered orally will be assessed by incidence and severity of adverse events (AEs), abnormalities in clinical laboratory assessments, ECGs, vital sign assessments, and physical exams.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The PK of SYHX1901 following single-dose and multiple doses</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>Peak Plasma Concentration (Cmax) of SYHX1901 following single-dose and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PK of SYHX1901 following single-dose and multiple doses</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of SYHX1901 following single-dose and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PK of SYHX1901 following single-dose and multiple doses</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>The concentration peak time of SYHX1901 following single-dose and multiple doses&#xD;
Concentration peak time&#xD;
The peak time of SYHX1901 concentration following single-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PK of SYHX1901 following single-dose and multiple doses</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>The half-time of SYHX1901 following single-dose and multiple doses&#xD;
The half - time of SYHX1901 following single-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PK of SYHX1901 following single-dose and multiple doses</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>The plasma clearance rate （CL）of SYHX1901 following single-dose and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK parameters</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the dose（180 mg）</time_frame>
    <description>Urine pharmacokinetic parameters: The Urine clearance rate （CLr）of SYHX1901</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK parameters</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the dose（180 mg）</time_frame>
    <description>Urine pharmacokinetic parameters: Cumulative excretion from time t1 to t2(Aet1-t2)&#xD;
Fecal pharmacokinetic parameters:Cumulative excretion from time t1 to t2&#xD;
Urine pharmacokinetic parameters:cumulative excretion from time t1 to t2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal PK parameters</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the dose（180 mg）</time_frame>
    <description>Fecal pharmacokinetic parameters: cumulative excretion from time t1 to t2(Aft1-t2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of Metabolites of SYHX1901</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the dose（180 mg）</time_frame>
    <description>It is a prospective study aiming to characterize metabolites of 1901 in human plasma, urine and feces. The metabolism profiles of 1901 and main metabolites will be build up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD indexes: the level of PSTATs in blood cells</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>Pharmacodynamic indexes: the level of PSTATs in blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD indexes: the inhibition rate of PSTATs in blood cells</measure>
    <time_frame>Pre-dose and multiple timepoints up to 144 hours after the last dose</time_frame>
    <description>Pharmacodynamic indexes: the inhibition rate of PSTATs in blood cells</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>SYHX 1901 tablets for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subjects will be enrolled in a single dose group which is recommended as the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of SYHX 1901 tablets in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 out of 10 healthy subjects will be randomized to receive a single dose of placebo in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYHX 1901 tablets for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 out of 10 healthy subjects will be randomized to receive multiple doses of SYHX 1901 tablets in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 out of 10 healthy subjects will be randomized to receive multiple doses of placebo in fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHX 1901 tablets</intervention_name>
    <description>SYHX 1901, oral tablets, in fasted state</description>
    <arm_group_label>SYHX 1901 tablets for MAD</arm_group_label>
    <arm_group_label>SYHX 1901 tablets for SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo, oral tablets, in fasted state</description>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_label>Placebo for SAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged 18 to 45 years (inclusive)；&#xD;
&#xD;
          2. Have a body mass index (BMI) between 18.0 and 26.0 kg/m2 (inclusive) and weigh at&#xD;
             least 45.0 kg (female) or 50.0 kg (male) at screening；&#xD;
&#xD;
          3. Satisfactory medical assessment with no clinically significant or relevant&#xD;
             abnormalities as determined by medical history, vital signs, physical examination, and&#xD;
             clinical laboratory tests (hematology, urinalysis, and coagulation)；&#xD;
&#xD;
          4. Subjects and their partners agree to use effective n4. Subjects and their partners&#xD;
             agree to use effective non-hormonal contraceptive measures (e.g., condoms, inert&#xD;
             intrauterine devices, female barriers (cervix cap or diaphragm with spermicide),&#xD;
             vaginal contraceptive ring, etc.) from signing the informed consent form to 6 months&#xD;
             after the end of the study, or have taken permanent contraceptive measures (e.g.,&#xD;
             bilateral fallopian tube ligation, vasectomy, etc.); male subjects have no sperm&#xD;
             donation plan from signing the informed consent to 6 months after the end of the&#xD;
             study, female subjects have no egg donation plan from signing the informed consent&#xD;
             form to 6 months after the end of the study；&#xD;
&#xD;
          5. Subjects who fully understand the study, voluntarily participate in the trial and sign&#xD;
             the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior neurological/ psychiatric, respiratory system, endocrine system, blood system,&#xD;
             skeletal-muscular system diseases or liver and kidney dysfunction or other diseases&#xD;
             that may affect the results of the study;&#xD;
&#xD;
          2. History of severe allergies, herpes zoster infection, or tuberculosis;&#xD;
&#xD;
          3. Those who have taken any prescription drugs, over-the-counter drugs, proprietary&#xD;
             Chinese medicines, herbal medicines, vitamin dietary supplements and health products&#xD;
             within 4 weeks before signing the informed consent, and those who use oral long-acting&#xD;
             contraceptives or use embedded long-acting contraceptives；&#xD;
&#xD;
          4. Subjects with diseases affecting drug absorption, distribution, metabolism and&#xD;
             excretion as judged by investigator (e.g., acute and chronic diarrhea, acute and&#xD;
             chronic gastritis, etc.);&#xD;
&#xD;
          5. Surgery history within 6 months prior to signing the informed consent;&#xD;
&#xD;
          6. Subjects with surgery plan (including cosmetic surgery, dental surgery and oral&#xD;
             surgery), or strenuous exercise plan (including physical contact sports or collision&#xD;
             sports) during the trial period;&#xD;
&#xD;
          7. Subjects with any clinically significant abnormalities in ECG, QTcF interval greater&#xD;
             than 450 ms (male) or 470 ms (female), or with a history of prolonged QTcF interval;&#xD;
&#xD;
          8. Subjects with one or more abnormalities in the vital signs at screening: ear&#xD;
             temperature &gt;37.5ºC, pulse rate &gt;100 beats/min, systolic blood pressure ≥140 mmHg or&#xD;
             &lt;90 mmHg, diastolic blood pressure &gt;90 mmHg or &lt;50 mmHg；&#xD;
&#xD;
          9. The white blood cell count, the absolute value of neutrophils and the absolute value&#xD;
             of lymphocytes are below the lower limit or higher than the upper limit of the&#xD;
             reference value, and the percentage of reticulocyte (RET) is below the lower limit of&#xD;
             the reference value in routine blood tests at screening;&#xD;
&#xD;
         10. History of acute respiratory or systemic infections within 2 weeks before signing the&#xD;
             informed consent;&#xD;
&#xD;
         11. Blood lost or donation more than 400 mL within 3 months before signing the informed&#xD;
             consent;&#xD;
&#xD;
         12. Alcohol abuse: consumption of more than 14 units of alcohol per week within 4 weeks&#xD;
             prior to signing the informed consent or positive test for Alcohol at screening；&#xD;
&#xD;
         13. Smoker: more than 5 cigarettes per day within 6 months prior to signing informed&#xD;
             consent；&#xD;
&#xD;
         14. Habitual intake of excessive xanthine- or caffeine-containing food, beverages, or&#xD;
             other factors, which may interfere the absorption, distribution, metabolism, or&#xD;
             excretion of drugs, within 4 weeks prior to screening；&#xD;
&#xD;
         15. Subjects have participated in clinical trials of any drug or medical device within 3&#xD;
             months before signing the informed consent;&#xD;
&#xD;
         16. History of substance abuse within the 1 years prior to signing the informed consent,&#xD;
             or positive test for drug abuse at screening；&#xD;
&#xD;
         17. Female subjects who are pregnant or lactating;&#xD;
&#xD;
         18. Anti-Mullerian hormone (female only) test results not within the reference range at&#xD;
             screening;&#xD;
&#xD;
         19. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody&#xD;
             (anti-HCV), Human immunodeficiency virus antibody (anti-HIV) or Treponema Pallidum&#xD;
             antibody (Anti-TP) at screening；&#xD;
&#xD;
         20. Suspected or known allergy to the test drug or any ingredient in the test drug, or&#xD;
             subjects with allergic constitution;&#xD;
&#xD;
         21. Not suitable for this trial as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jing zhang, Medical PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ying hu, master</last_name>
    <phone>15021575058</phone>
    <email>hyy1102030@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying hu, master</last_name>
      <phone>15021575058</phone>
      <email>hyy1102030@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

